Evaluation of the effects of rivastigmine on cigarette smoking by methamphetamine-dependent volunteers

Compared to smokers alone, smokers with co-morbid substance use disorders are at greater risk of suffering from smoking-related death. Despite this, relatively few studies have examined smoking cessation treatments for those with stimulant dependence. In the current study, we sought to evaluate the...

Full description

Saved in:
Bibliographic Details
Published in:Progress in neuro-psychopharmacology & biological psychiatry 2011-12, Vol.35 (8), p.1827-1830
Main Authors: De La Garza, R., Yoon, J.H.
Format: Article
Language:English
Subjects:
Acetylcholine
Addiction
Addictive behaviors
Adolescent
Adult
Adult and adolescent clinical studies
Amphetamine-Related Disorders - complications
Biological and medical sciences
Cholinesterase Inhibitors - therapeutic use
Cross-Over Studies
Double-Blind Method
Drug addiction
Humans
Medical sciences
Methamphetamine
Middle Aged
Neuropharmacology
Nicotine-dependence
Pharmacology. Drug treatments
Phenylcarbamates - therapeutic use
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Rivastigmine
Smoking
Smoking - drug therapy
Smoking Cessation - methods
Tobacco smoking
Tobacco Use Disorder - complications
Tobacco Use Disorder - drug therapy
Tobacco, tobacco smoking
Toxicology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Compared to smokers alone, smokers with co-morbid substance use disorders are at greater risk of suffering from smoking-related death. Despite this, relatively few studies have examined smoking cessation treatments for those with stimulant dependence. In the current study, we sought to evaluate the effects produced by short-term exposure to the cholinesterase inhibitor rivastigmine (0, 3 or 6mg) on cigarette smoking in non-treatment-seeking, methamphetamine-dependent volunteers. This was a double-blind, placebo-controlled, crossover study that took place over 9days. The data indicate that rivastigmine treatment did not alter Fagerström Test for Nicotine Dependence scores, carbon monoxide readings, or cigarettes smoked per day, but a trend toward reduced urges to smoke (p
ISSN:0278-5846
1878-4216
DOI:10.1016/j.pnpbp.2011.07.006